Ferdinand Keith C, Yadav Kapil, Nasser Samar A, Clayton-Jeter Helene D, Lewin John, Cryer Dennis R, Senatore Fortunato Fred
Tulane Heart and Vascular Institute, Tulane University School of Medicine, New Orleans, LA, USA.
Department of Clinical Research & Leadership, School of Medicine and Health Sciences, The George Washington University, Washington, DC, USA.
J Clin Hypertens (Greenwich). 2017 Oct;19(10):1015-1024. doi: 10.1111/jch.13089. Epub 2017 Aug 30.
Blacks are two to three times as likely as whites to die of preventable heart disease and stroke. Declines in mortality from heart disease have not eliminated racial disparities. Control and effective treatment of hypertension, a leading cause of cardiovascular disease, among blacks is less than in whites and remains a challenge. One of the driving forces behind this racial/ethnic disparity is medication nonadherence whose cause is embedded in social determinants. Eight practical approaches to addressing medication adherence with the potential to attenuate disparities were identified and include: (1) patient engagement strategies, (2) consumer-directed health care, (3) patient portals, (4) smart apps and text messages, (5) digital pillboxes, (6) pharmacist-led engagement, (7) cardiac rehabilitation, and (8) cognitive-based behavior. However, while data suggest that these strategies may improve medication adherence, the effect on ameliorating racial/ethnic disparities is not certain. This review describes the relationship between disparities and medication adherence, which likely plays a role in persistent disparities in cardiovascular morbidity and mortality.
黑人死于可预防的心脏病和中风的可能性是白人的两到三倍。心脏病死亡率的下降并未消除种族差异。高血压是心血管疾病的主要原因之一,黑人对其的控制和有效治疗情况不如白人,仍然是一项挑战。这种种族/族裔差异背后的一个驱动因素是药物治疗依从性差,其根源在于社会决定因素。确定了八种有可能减少差异的解决药物治疗依从性的实用方法,包括:(1)患者参与策略,(2)消费者主导的医疗保健,(3)患者门户,(4)智能应用程序和短信,(5)电子药盒,(6)药剂师主导的参与,(7)心脏康复,以及(8)基于认知的行为。然而,虽然数据表明这些策略可能会提高药物治疗依从性,但对改善种族/族裔差异的效果尚不确定。本综述描述了差异与药物治疗依从性之间的关系,这可能在心血管疾病发病率和死亡率的持续差异中起作用。